Ibrance for pancreatic cancer – pro
On April 15, 2015 Pfizer Inc. (NYSE:PFE) announced that the Phase 3 PALOMA-3 trial for IBRANCE® (palbociclib) met its primary endpoint of demonstrating an improvement in progression-free survival (PFS) for the combination of IBRANCE plus fulvestrant compared with fulvestrant plus placebo in women with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer following disease progression during or after endocrine therapy. The study was stopped early due to efficacy based on an assessment by an independent Data Monitoring Committee (DMC). These are the first randomized Phase 3 trial results for IBRANCE, a new anti-cancer medicine with the novel mechanism of cyclin-dependent kinase 4/6 (CDK 4/6) inhibition.
IBRANCE was approved by the U.S. Food and Drug Administration (FDA) in February 2015 as a first-line treatment for women with advanced or metastatic estrogen receptor positive, human epidermal growth factor receptor 2 negative (ER+/HER2-) breast cancer. IBRANCE® (palbociclib), in combination with letrozole, is indicated for the treatment of postmenopausal women with ER+/HER2- advanced breast cancer as initial endocrine-based therapy for their metastatic disease.
I found a few preliminary articles on the use of Ibrance for pacnreatic and biliary cancers.. Al Baghdadi et la looked at 10 patients with pancreatic and biliary cancer, respectively, with CDKN2A loss or mutation who were treated with palbociclib. There was no clinical activity.
T. Al Baghdadi et al, Palbociclib in Patients With Pancreatic and Biliary Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study. DOI: 10.1200/PO.19.00124 JCO Precision Oncology – published online August 14, 2019
https://news.cornell.edu/stories/2020/02/new-chemo-combo-shows-promise-versus-pancreatic-cancer, 2/2020
https://www.mskcc.org/news/drug-combination-could-boost-effectiveness-immunotherapy-against-pancreaticm March 31, 2020